XTL Biopharmaceuticals LTD cash flow statement

In fiscal 2024, XTL Biopharmaceuticals LTD's operations generated −$1.6m of cash; it spent $54,000 on capital projects, leaving free cash flow of −$1.7m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

XTL Biopharmaceuticals LTD: cash flow statement, annual
Fiscal year	2024Dec 2024
Cash from operations	−1,618
Depreciation and amortisation	199
Stock-based pay	264
Capital spending	54
Free cash flow	−1,672
Free cash flow after stock pay	−1,936

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from XTL Biopharmaceuticals LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to XTL Biopharmaceuticals LTD.